ulcerative colitis

[Connect Biopharma Holdings Ltd.] Connect Biopharma Holdings Limited announced that it has completed full enrollment of the phase II clinical trial evaluating CBP-307 in adult patients with moderate-to-severe ulcerative colitis.

[Pharmacological Research] The research and development of new drugs for the treatment of ulcerative colitis is urgent, and natural alkaloids are an important source.

[Advanced Science] A biphasic hyaluronan (HA) enema suspension, naïve-HA system that protected the dysregulated gut epithelium by decreasing the inflammation, permeability, and helping in maintaining the epithelial barrier integrity in the dextran sodium sulfate-induced colitis mice model was reported.

[Journal of Gastroenterology and Hepatology] Studies are continuing to explore the role of fecal microbiota transplantation for many other conditions, including Crohn’s disease, functional gut disorders, metabolic syndrome, modulating responses to chemotherapy, eradication of multidrug resistant organisms, and the gut-brain axis.

[Immunic, Inc.] Immunic, Inc. announced that the final patient has been enrolled and randomized in its phase II CALDOSE-1 trial of lead asset, IMU-838, the company's selective oral DHODH inhibitor, in patients with moderate-to-severe ulcerative colitis.

[Bristol Myers Squibb] Bristol Myers Squibb announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Zeposia for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.